

**Nanopore Community Meeting 2016**  
New York



**JOHNS HOPKINS**  
BIOMEDICAL ENGINEERING

# **Structural variation detection on human DNA using targeted sequencing**


Isac Lee

Department of Biomedical Engineering, Johns Hopkins School of Medicine

December 2, 2016


# Structural Variation

- Abnormality in large region (50b-3mb) of a chromosome
- Pervasive in cancer – 50% of pancreatic ductal adenocarcinoma (PDAC)
- Common in tumor suppressor genes such as *CDKN2A* and *SMAD4*
- Nanopore sequencing can resolve SVs
  - *But* High coverage desired for heterogeneous samples
  - and size of human genome : 3 Gbps
- We know where SVs tends to occur



Baker, Monya. 2012. Nature Methods

# Solution-phase Hybridization Capture



## Agilent SureSelectXT Targeted Sequencing System



**Agilent Technologies**

- ~90 bps biotinylated RNA probes complementary to target sequence
- Biotin-streptavidin interaction to enrich for the targeted region
- Optimization for long-reads : > 2 kb




# Targeted Capture Optimization

Collaboration with Josh Wang from Agilent

- Trial 1
  - Probe tiling, No empty spaces between probes
  - Target region
    - *CDKN2A* : 1.5 Mbps
  - Low stringency to allow mismatches
  - Result: 2.28 % on-target
- Trial 2
  - No tiling, average 400 bp space between probes
  - Target regions
    - *CDKN2A* : 1.5 Mbps
    - *SMAD4* : 850 Kbps
  - High stringency to limit off-target capture
  - Consideration of known SV breakpoints
    - PDAC SVs from James Eshleman lab
  - Result: 30 % on-target

# Targeted Sequencing Performance

- Control : NA12878 lymphoblast
- Sample : PDAC from Eshleman lab
- Illumina short-read targeted sequencing for comparison
- > 300-fold enrichment
- > 20X average coverage





	Total yield (reads)	On-target	On-target percentage	Fold enrichment	Coverage
Illumina NA12878	4.4m	3.7m	85%	641X	113X
Nanopore NA12878	107k	32k	30%	353X	27X
Nanopore PDAC	56k	20k	26%	332X	20X

# Nanopore Structural Variation Detection

NA12878 SVs

Sniffles by Michael Schatz lab



- chr9:21,038,354 - 21,038,506
- 152 bps duplication
- Validated with PacBio data from Genome in a Bottle (Mt. Sinai School of Medicine)



# Nanopore Structural Variation Detection

## PDAC SVs

- Novel, putative SVs detected from PDAC
- chr18: 51,198,535 – 51,199,143
- 600 bps deletion
- Possibly allele-specific SV



# Nanopore Structural Variation Detection

## PDAC SVs

Large window of coverage

Absence in *CDKN2A* region


○ chr9:21,950,000 - 22,436,000

○ 486 kbps SV


○ Homozygous Deletion discovered previously

Sniffles did not detect this SV

○ No reads covering either breakpoint



### *CDKN2A* Structural Variation





# Single Nucleotide Variation Detection


## NA12878 SNVs

- Nanopolish by Jared Simpson et al to improve SNV calling

SNV comparisons

	Illumina	Pre-polish	Post-polish
Avg. Coverage	113	27	27
Correct	1133	2485	947
Total	1211	4138	1017
Precision	<b>94%</b>	60%	<b>93%</b>
Sensitivity	<b>32%</b>	69%	<b>26%</b>

Number of True SNVs: 3587 (Eberle, et al. bioRxiv, 2016)



- Nanopore SNV detection after nanopolish is comparable to Illumina
- Phased SNV analysis is possible with coverage from targeted sequencing

# Conclusions and Future Works

## Solution-phase Hybridization-Capture

- Achieves sufficient coverage for SV and SNV detection
- Longer reads and higher on-target percentage : recent run 40% on-target, 3kb avg. length

## Structural Variation Detection

- SVs can be detected with a single flowcell
- Allele-specific SVs may also be resolved

## Single Nucleotide Variation Detection

- SNV detection is comparable to Illumina sequencing
- Nanopolish for haplotyping and phased SNV analysis

# Acknowledgments



**JOHNS HOPKINS**  
WHITING SCHOOL  
*of* ENGINEERING

**Timp Lab – Johns Hopkins University**  
Winston Timp, PhD  
Rachael Workman, MS



**Agilent Technologies**

**Agilent Technologies**  
Josh Wang, PhD  
Jonathan Levine, PhD



**JOHNS HOPKINS**  
SCHOOL *of* MEDICINE

**Eshleman Lab – Johns Hopkins School of Medicine**  
James Eshleman, MD, PhD  
Alexis Norris, PhD